Data Updates in the Treatment of Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

Expert panelists review updated data in the identification and management of resectable cutaneous squamous cell carcinoma and reflect on how real-world practice has evolved.

EP. 1: Cutaneous Squamous Cell Carcinoma: Incidence and Risk Factors

March 15th 2023

Opening their discussion on resectable cutaneous squamous cell carcinoma (CSCC), expert panelists elucidate its current incidence and known risk factors.

EP. 2: Available Staging Systems for Cutaneous Squamous Cell Carcinoma

March 15th 2023

A review of current staging systems used to categorize CSCC, particularly those from the American Joint Committee on Cancer and Brigham and Women's Hospital.

EP. 3: Optimal Risk Stratification in Patients With Cutaneous Squamous Cell Carcinoma

March 22nd 2023

Expert panelists share their perspectives on best strategies to risk stratify patients diagnosed with cutaneous squamous cell carcinoma.

EP. 4: Defining Resectability in CSCC

March 22nd 2023

Following their discussions on staging and risk stratification in CSCC, key opinion leaders work to define resectability in cutaneous squamous cell carcinoma.

EP. 5: Staging and Risk Stratification’s Impact on Treatment Approach in CSCC

March 29th 2023

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

EP. 6: Real World Experience With Resectable Cutaneous Squamous Cell Carcinoma

March 29th 2023

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

EP. 7: Evolving Treatment Paradigm of Resectable CSCC

April 5th 2023

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

EP. 8: Clinical Experience With Neoadjuvant IO Therapy in Melanoma

April 5th 2023

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

EP. 9: Lessons Learned in Other Cancers and Suggested Endpoints in Future Trials

April 12th 2023

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

EP. 10: Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data Updates

April 12th 2023

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

EP. 11: CSCC: Translating Cemiplimab Data Into Practice

April 19th 2023

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

EP. 12: Other Emerging Treatment Modalities in Cutaneous Squamous Cell Carcinoma

April 19th 2023

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

EP. 13: Best Practices in Multidisciplinary Care for CSCC

April 26th 2023

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

EP. 14: CSCC: Escalating Therapy for High-risk Patients

April 26th 2023

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

EP. 15: Practical Advice on the Evolving Management of CSCC

May 3rd 2023

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.